Showing results (121-130 of 226) with videos related to

Sort By:
Pageof 23
Schizophrenia Research|October 27, 2009
Amplitude of low-frequency oscillations in schizophrenia: a resting state fMRI studyMatthew J Hoptman, Xi-Nian Zuo, Pamela D Butler, et al.
Blood|September 27, 2003
Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylateMichael E O'Dwyer, Michael J Mauro, Carolyn Blasdel, et al.
Journal of Cancer Research and Clinical Oncology|January 27, 2023
Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitorsEhab Atallah, Michael J Mauro, Andreas Hochhaus, et al.
RNA (New York, N.Y.)|May 18, 2019
Nonlinear sequence similarity between the Xist and Rsx long noncoding RNAs suggests shared functions of tandem repeat domainsDaniel Sprague, Shafagh A Waters, Jessime M Kirk, et al.
The Oncologist|September 28, 2011
Will imatinib compromise reproductive capacity?Alberuni M Zamah, Michael J Mauro, Brian J Druker, et al.
Acta Odontologica Latinoamericana : AOL|October 5, 2016
Repairability of aged resin composites mediated by different restorative systemsCleidiel Aa Lemos, Sílvio J Mauro, Renata A de Campos, et al.
Biorxiv : the Preprint Server for Biology|December 3, 2025
Early Host-Virus RNA Interactions Reveal SPEN-Driven m 6 A Regulation as a Major Determinant of Henipavirus InfectionAndrea Ascura, Stephen Clarke, Andrew F Livingston, et al.
Disease Models & Mechanisms|September 29, 2025
Noncoding and coding mechanisms of aging-related heart failure with preserved ejection fraction associated with thyroid dysfunctionSankalpa Chakraborty, Olivia Sloan, Bryce Dickerson, et al.
Blood|August 15, 2002
The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CMLMichael E O'Dwyer, Michael J Mauro, Gwen Kurilik, et al.
European Journal of Haematology|February 27, 2021
Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapyJorge E Cortes, Hagop M Kantarjian, Michael J Mauro, et al.
Pageof 23